- 1) The family history or tumor type is suggestive of a predisposition to pediatric cancer. The OncoGeneDx Pediatric Tumor Panel offers increased clinical sensitivity compared to testing only for the genes most commonly associated with pediatric cancer susceptibility. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering TP53 testing followed by additional genetic testing, if negative).
- 2) The differential diagnosis includes various hereditary cancer syndromes. For example, if the childâ€™s personal and/or family history consists of multiple types of tumors or cancer such as a pediatric brain tumor in addition to a hematological malignancy, this may be associated with a cancer syndrome such as Liâ€Fraumeni syndrome or CMMRâ€D syndrome.
- 3) Genetic testing has already been ordered due to a personal or family history suggestive of a hereditary cancer predisposition and all results have been negative. OncoGeneDx Pediatric Tumor Panel includes genes whose role in cancer predisposition has been described recently in addition to genes associated with classic hereditary cancer syndromes.